As of June 21, 2025, Vifor Pharma AG (VIFN.SW) reports a Forward P/E of 44.87.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Vifor Pharma AG's Forward P/E to Peers
To better understand Vifor Pharma AG's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Vifor Pharma AG (VIFN.SW) | 44.87 |
| HUTCHMED (China) Ltd (HCM.L) | 5601.09 |
| Dechra Pharmaceuticals PLC (DPH.L) | 3038.99 |
| Alliance Pharma PLC (APH.L) | 1284.82 |
| Hikma Pharmaceuticals PLC (HIK.L) | 1234.85 |
| Indivior PLC (INDV.L) | 1050.61 |
Compared to its competitors, Vifor Pharma AG's Forward P/E is about average compared to peers, indicating growth expectations in line with industry peers.